TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33068667

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Listening to a news article (Control)
Number of subjects: 126
Study: 32065939

Group type: EXPERIMENTAL
Intervention: COPE (integrated treatment using prolonged exposure)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Seeking Safety (integrated therapy using cognitive behavioral, interpersonal techniques and case management)
Number of subjects: 119
Study: 35074903

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg) + Nivolumab (1 mg/kg)
Number of subjects: 19
Study: 33663610

Group type: EXPERIMENTAL
Intervention: Mediterranean/Low Carbohydrate (MED/LC) diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low Fat (LF) diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful weight losers (> 5% weight loss)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Weight-loss failures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Participants with healthy liver fat content (< 5% IHF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Participants with fatty liver
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall weight-loss lifestyle intervention
Number of subjects: 120
Study: 616191276

Group type: COMPARATOR
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Varenicline (1 gm twice daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Varenicline + Bupropion (1 gm twice daily + 150 mg twice daily)
Number of subjects: 300
Study: 36262221

Group type: EXPERIMENTAL
Intervention: Adapted person-centered prescription (PCP) model
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 32895890

Group type: EXPERIMENTAL
Intervention: Cognitive training delivered using CoRe software (CCT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional paper-and-pencil cognitive training (PCT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unstructured activity intervention (CG)
Number of subjects: 53
Study: 35063621

Group type: EXPERIMENTAL
Intervention: 2 litres per minute of air in front of mouth/nose into the air pocket
Number of subjects: 20

Group type: COMPARATOR
Intervention: No air
Number of subjects: 20
Study: 34002406

Group type: EXPERIMENTAL
Intervention: Professional-guided bibliotherapy sessions (8 weekly sessions)
Number of subjects: 60
Study: 35061868

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) for 9 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Online discussion forum (ODF)
Number of subjects: 144
Study: 34894454

Group type: EXPERIMENTAL
Intervention: ctDNA undetectable at week 8
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ctDNA undetectable at week 8 in patients with stable disease (SD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: ctDNA undetectable vs detectable in patients with PR at week 8
Number of subjects: 86

Group type: COMPARATOR
Intervention: ctDNA undetectable vs detectable in patients with SD at week 8
Number of subjects: 86
Study: 33290772

Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 μg (VP250)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 μg (VP100)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (PLB) followed by Viaskin Peanut 250 μg (PLB-VP250)
Number of subjects: 130
Study: 615918678

Group type: EXPERIMENTAL
Intervention: 532 nm laser exposure during driving tests
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sun visor folded down during laser exposure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Driving without laser exposure
Number of subjects: 10
Study: 35263172

Group type: EXPERIMENTAL
Intervention: Intra-operative detection of pathogens in subcutaneous tissue
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Intra-operative detection of Enterococcus faecium
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Positive subcutaneous swab
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Pre-operative anemia
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 393
Study: 33496955

Group type: EXPERIMENTAL
Intervention: Barbed extra-mucosal running suture (stapler-less)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard stapler line
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques (stapler-less and standard stapler)
Number of subjects: 40
Study: 32100683

Group type: EXPERIMENTAL
Intervention: VAPE® portable set (spatial repellent device)
Number of subjects: 21
Study: 35483627

Group type: EXPERIMENTAL
Intervention: Tongxie
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 33879733

Group type: EXPERIMENTAL
Intervention: rhBNP group (basic treatment combined with rhBNP)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: sequential treatment group (basic treatment for heart failure combined with rhBNP followed by sacubitril/valsartan)
Number of subjects: 300

Group type: COMPARATOR
Intervention: standard treatment group (treated with an angiotensin‐converting enzyme inhibitor, β receptor blocker, and corticosteroid antagonist)
Number of subjects: 300
Study: 34253665

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 60
Study: 34970718

Group type: COMPARATOR
Intervention: rTMS‐COG (repetitive transcranial magnetic stimulation combined with cognitive training)
Number of subjects: 72

Group type: COMPARATOR
Intervention: rTMS‐COG
Number of subjects: 72

Group type: COMPARATOR
Intervention: EEG parameters
Number of subjects: 72
Study: 33574075

Group type: EXPERIMENTAL
Intervention: CT model for lung cancer incidence
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Final model for lung cancer incidence
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: CT model for lung cancer incidence (validation cohort)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Final model for lung cancer incidence (validation cohort)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Final model for CVD mortality
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Survey model for CVD mortality
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: CT model for CVD mortality
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Final model for COPD mortality
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Survey model for COPD mortality
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: CT model for COPD mortality
Number of subjects: 15000
Study: 32073202

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Art Therapy (MBAT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Neutral Clay Task (NCT)
Number of subjects: 77
Study: 35382758

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General Health Education (GHE)
Number of subjects: 30
Study: 34057373

Group type: EXPERIMENTAL
Intervention: I-PLAN intervention (information about consequences of hearing aid use/nonuse, reminder prompt, action plan)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: I-PLAN intervention
Number of subjects: 160
Study: 32145994

Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 89

Group type: COMPARATOR
Intervention: HD-IIV3
Number of subjects: 89

Group type: COMPARATOR
Intervention: aIIV3
Number of subjects: 89
Study: 34708311

Group type: EXPERIMENTAL
Intervention: Prophylactic extraoral photobiomodulation (PBM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 33351346

Group type: COMPARATOR
Intervention: NAD(P)-dependent dehydrogenases activity in newly diagnosed GD patients
Number of subjects: 151

Group type: COMPARATOR
Intervention: NAD(P)-dependent dehydrogenases activity in GD relapse group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation between fT3 level and MDG activity in newly diagnosed GD patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation between fT4 level and NAD(P)-ICDH activity in newly diagnosed GD patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation between TSH concentration and LDH activity in GD relapse patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation between TSH concentration and MDH activity in GD relapse patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation between fT4 concentration and NADGDH activity in GD relapse patients
Number of subjects: 151
Study: 35768976

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (150 mg/day and 15 mg/kg every 3 weeks)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 152

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 152
Study: 34948846

Group type: EXPERIMENTAL
Intervention: HBM-based MI model intervention (7 counseling sessions)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 107
Study: 35099263

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Therapy Day Hospital (MBT-DH)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Mentalization-Based Therapy Intensive Outpatient (MBT-IOP)
Number of subjects: 114
Study: 34534623

Group type: EXPERIMENTAL
Intervention: Multicomponent training program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active control group (usual activities of the community service program)
Number of subjects: 27
Study: 35046397

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study: 32259774

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 300 mg twice daily for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 80
Study: 33924380

Group type: EXPERIMENTAL
Intervention: Canadian RCTs
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Canadian trials
Number of subjects: 155
Study: 33239330

Group type: EXPERIMENTAL
Intervention: Neuraxial anaesthesia
Number of subjects: 20988

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20988
Study: 36416836

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 832

Group type: COMPARATOR
Intervention: Ipilimumab or high-dose interferon α 2b (HDI)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 832

Group type: COMPARATOR
Intervention: High-dose interferon α 2b (HDI)
Number of subjects: 832
Study: 33650299

Group type: EXPERIMENTAL
Intervention: Selenious yeast tablet (SYT) for 6 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 32740288

Group type: EXPERIMENTAL
Intervention: 70% OHP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90% OHP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 70% DL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90% DL
Number of subjects: 30

Group type: COMPARATOR
Intervention: OHP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 70% 1RM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90% 1RM
Number of subjects: 30
Study: 33079411

Group type: EXPERIMENTAL
Intervention: Education plus sleeve compression/exercise intervention (lymphedema education and prevention [LEAP])
Number of subjects: 554

Group type: COMPARATOR
Intervention: Education-only (EO)
Number of subjects: 554
Study: 32939788

Group type: EXPERIMENTAL
Intervention: LAA exclusion group (n = 521)
Number of subjects: 860

Group type: COMPARATOR
Intervention: LAA nonexclusion group (n = 339)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: LAA exclusion in patients with AF
Number of subjects: 860

Group type: COMPARATOR
Intervention: LAA nonexclusion in patients without AF
Number of subjects: 860
Study: 36398729

Group type: EXPERIMENTAL
Intervention: Single-balloon-assisted colonoscopy (SBC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 44
Study: 34449280

Group type: EXPERIMENTAL
Intervention: Orthoptic exercises
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 488

Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 488

Group type: COMPARATOR
Intervention: Observation preference
Number of subjects: 488
Study: 32590658

Group type: EXPERIMENTAL
Intervention: Intensive feedback intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Simple feedback
Number of subjects: 7
Study: 35042007

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) augmentation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (sham incision)
Number of subjects: 80
Study: 34082593

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 40
Study: 33793636

Group type: EXPERIMENTAL
Intervention: High volume simethicone (1125 mg in 750 ml water)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard volume simethicone (300 mg in 200 ml water)
Number of subjects: 167
Study: 34616010

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 1039
Study: 33137473

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0
Study: 32232492

Group type: EXPERIMENTAL
Intervention: Workshop group (2-day training course)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multimedia group (educational content through video)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no training content)
Number of subjects: 90
Study: 35166429

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543
Study: 32539440

Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 6841

Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 6841
Study: 33622766

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) treatment (up to 1,200 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) treatment
Number of subjects: 61
Study: 32992151

Group type: EXPERIMENTAL
Intervention: Interim methadone (IM) + Patient Navigation (PN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interim methadone (IM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Treatment-As-Usual (ETAU)
Number of subjects: 0
Study: 35779610

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) for 3 months
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) for 12 months
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 33887262

Group type: EXPERIMENTAL
Intervention: Infliximab continued (5 mg/kg every 8 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Infliximab discontinued
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Infliximab continued
Number of subjects: 95

Group type: COMPARATOR
Intervention: Infliximab discontinued (retreatment)
Number of subjects: 95
Study: 32479135

Group type: EXPERIMENTAL
Intervention: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in mouse models.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in a mouse model of psoriasis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRM02 treatment of cultured primary human and mouse epidermal keratinocytes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRM02 treatment of human peripheral blood mononuclear cells ex vivo and cultured THP-1 monocyte-like cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRM02 treatment in relation to NF-κB transcriptional activity.
Number of subjects: 0
Study: 35189669

Group type: EXPERIMENTAL
Intervention: Repeat colonoscopy with adequate bowel preparation
Number of subjects: 651
Study: 34793639

Group type: EXPERIMENTAL
Intervention: QLB group (20 mL of 0.375% ropivacaine)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (saline solution)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study: 35137791

Group type: EXPERIMENTAL
Intervention: Himalayan Salt (HS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Common Salt (TS)
Number of subjects: 17
Study: 33305626

Group type: EXPERIMENTAL
Intervention: 50000 IU vitamin D weekly for 12–14 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 34
Study: 35953878

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg for men, 0.85 g/kg for women)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34753752

Group type: EXPERIMENTAL
Intervention: Mental health specialist video consultations (MHSVC) in primary care
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mental health specialist video consultations (MHSVC)
Number of subjects: 13
Study: 32843286

Group type: EXPERIMENTAL
Intervention: Vestronidase alfa, rhGUS enzyme replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36178972

Group type: EXPERIMENTAL
Intervention: Behavioral symptom management intervention (prototype including traditional coping skills, home-based physical activity, Acceptance and Commitment Therapy, Meaning-Centered Psychotherapy, self-compassion strategies)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: User testing sessions of the prototype intervention materials (paper manual and mobile application)
Number of subjects: 31
Study: 34384515

Group type: EXPERIMENTAL
Intervention: Healthy food and drink policy implemented at scale in hospitals
Number of subjects: 4808

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 4808
Study: 32916985

Group type: EXPERIMENTAL
Intervention: Low Calorie Mediterranean (LoCalMed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 32648260

Group type: EXPERIMENTAL
Intervention: CNS relapse treatment (heterogeneous)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 618

Group type: COMPARATOR
Intervention: CNS involvement at diagnosis
Number of subjects: 618

Group type: COMPARATOR
Intervention: Bone marrow involvement and peripheral blasts
Number of subjects: 618
Study: 32469373

Group type: EXPERIMENTAL
Intervention: Power Posing (experimental group): Subjects stood with hands on hips, elbows pointing out, and feet approximately 1 foot apart for 20 seconds.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group: Subjects stood with hands and arms wrapping around the torso and feet together for 20 seconds.
Number of subjects: 0
Study: 34864649

Group type: EXPERIMENTAL
Intervention: Timolol nasal spray (1 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Benzalkonium chloride)
Number of subjects: 20
Study: 36454906

Group type: EXPERIMENTAL
Intervention: Blueberry (250 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 20
Study: 32672508

Group type: EXPERIMENTAL
Intervention: Flat specialists riding on flat (0% gradient)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Uphill specialists riding uphill (6% gradient)
Number of subjects: 19
Study: 35806977

Group type: EXPERIMENTAL
Intervention: Topographical landmarks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Radiological landmarks
Number of subjects: 120
Study: 33970286

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) using CT for patient selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT combined with CT angiography (CTA) or additional perfusion imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI as first-line choice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT imaging with perfusion imaging
Number of subjects: 0
Study: 32967713

Group type: EXPERIMENTAL
Intervention: SOLAS intervention (theory-driven group-based complex intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual individual physiotherapy (UP; pragmatic control group)
Number of subjects: 120
Study: 35500513

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midazolam (MID)
Number of subjects: 42
Study: 32891496

Group type: EXPERIMENTAL
Intervention: HAs featuring LFT
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional HAs featuring wide dynamic range compression (control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: HAs employing both LFT and wide dynamic range compression of high frequencies (combined group)
Number of subjects: 103
Study: 35960070

Group type: EXPERIMENTAL
Intervention: High-definition white light colonoscopy (HD-WLC)
Number of subjects: 553

Group type: COMPARATOR
Intervention: 190-narrow-band imaging (190-NBI)
Number of subjects: 553
Study: 33787042

Group type: EXPERIMENTAL
Intervention: Pectin-containing enteral formula (Hine E-Gel®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard polymeric formula (Ensure®)
Number of subjects: 30
Study: 32502172

Group type: EXPERIMENTAL
Intervention: Persian version of The Baruth Protective Factors Inventory
Number of subjects: 200
Study: 35870947

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1 g Taurine, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 120
Study: 35340032

Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra for 14 days, pentoxifylline for 28 days, zinc for 180 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone for 28 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra, pentoxifylline, zinc)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone)
Number of subjects: 104
Study: 33514368

Group type: EXPERIMENTAL
Intervention: Pyronaridine‐artesunate (PA)
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Artemether–lumefantrine (AL)
Number of subjects: 1379